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Abstract
Objective: To develop, validate, and apply a method for
the determination of platinum contamination, originating
from cisplatinum, oxaliplatinum, and carboplatinum.
Methods: Inductively coupled plasma mass spectrometry
(ICP-MS) was used to determine platinum in wipe samples.
The sampling procedure and the analytical conditions were
optimised and the assay was validated. The method was
applied to measure surface contamination in seven Dutch
hospital pharmacies.
Results: The developed method allowed reproducible
quantiWcation of 0.50 ng l¡1 platinum (5 pg/wipe sample).
Recoveries for stainless steel and linoleum surfaces ranged
between 50.4 and 81.4% for the diVerent platinum com-
pounds tested. Platinum contamination was reported in
88% of the wipe samples. Although a substantial variation
in surface contamination of the pharmacies was noticed, in
most pharmacies, the laminar-airXow (LAF) hoods, the
Xoor in front of the LAF hoods, door handles, and handles
of service hatches showed positive results. This demon-
strates that contamination is spread throughout the prepara-
tion rooms.
Conclusion: We developed and validated an ultra sensi-
tive and reliable ICP-MS method for the determination of
platinum in surface samples. Surface contamination with
platinum was observed in all hospital pharmacies sampled.
The interpretation of these results is, however, complicated.
Keywords ICP-MS · Platinum · Validation · 
Hospital pharmacies · Surface contamination
Introduction
Cytotoxic drugs are widely used for the treatment of can-
cer. Occupational exposure to these drugs has been recog-
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nised as a potential health hazard since 1970s (Donner
1978; Falck et al. 1979). Because cytotoxic drugs can
aVect the DNA, RNA, or protein synthesis, many of these
drugs are classiWed as being carcinogenic, mutagenic, or
teratogenic to humans (International Agency for Research
on Cancer (IARC) 1997). Skin contact with cytotoxic
drugs, due to contamination of the work area or contamina-
tion of packaging material, seems to play an important role
in the uptake of these drugs by hospital personnel (Frans-
man et al. 2004; Sessink et al. 1994). Therefore, strict
health and safety rules have been established and applied
for the handling of these agents. Evidently, the potential
health risks for persons manipulating cytotoxic drugs, such
as pharmacists, pharmacy technicians, nurses, and cleaners,
however, still are a concern. This concern is consolidated
by a number of recent publications demonstrating work-
place contamination (Crauste-Manciet et al. 2005; Hedmer
et al.  2005; Leboucher et al. 2002; Mason et al. 2005;
Schmaus et al. 2002; Zeedijk et al. 2005; Ziegler et al.
2002) and contamination of packaging of cytotoxic drugs
(Connor et al. 2005; Hedmer et al. 2005; Mason et al.
2003; Nygren et al. 2002). Moreover, detection of cyto-
toxic agents in urine (Ensslin et al. 1994a, b, 1997; Minoia
et al. 1998; Pethran et al. 2003; Schreiber et al. 2003; Ses-
sink et al. 1994; Turci et al. 2002) and blood (Nygren and
Lundgren 1997) of personnel who were involved in prepa-
ration or administration has been reported with increasing
frequency.
The relationship between prolonged exposure to small
quantities of cytotoxic drugs and harmful eVects is diY-
cult to establish. Based on current scientiWc knowledge, it
is impossible to set a level of exposure that, beyond
doubt, will not cause adverse eVects. Because no regula-
tions on the maximal acceptable amount of contamina-
tion for these drugs have been set so far, hospitals should
aim for the lowest contamination as is reasonably achiev-
able. Monitoring of contamination, therefore, is essential.
This can aid in the identiWcation of the main exposure
routes and in assessing the eVectiveness of cleaning and
working procedures. Evaluation of environmental con-
tamination will, moreover, lead to an increase of the con-
sciousness among personnel, concerning the handling of
the chemotherapeutic agents. This can lead to an
improvement of and the compliance to working and
cleaning procedures. Wipe sampling is a common method
to monitor surfaces for the presence of cytotoxic drugs.
Hence, sensitive and validated methods are indispensable
to be able to detect the relatively low quantities of drug
present on surfaces.
Platinum coordination complexes, such as cisplatinum,
oxaliplatinum, and carboplatinum play a major role in the
treatment of a variety of tumours. As a result, large amounts
of these agents are processed in hospital pharmacies.
Several wipe sample methods for platinum containing
drugs have been used in earlier studies and platinum was
detected as a surface contaminant in many of the work-
places (Leboucher et al. 2002; Mason et al. 2005; Schmaus
et al. 2002; Ziegler et al. 2002) or drug vials (Connor et al.
2005; Nygren et al. 2002) investigated. A description of the
validation of the analytical methods, however, has been
scarce. Validation results were mentioned brieXy for the
method of Ziegler et al. (2002), using electro thermal
vaporisation coupled to inductively coupled plasma mass
spectrometry (ICP-MS). Raghavan et al. (2000) described
the validation of a high-performance liquid chromatogra-
phy method for the determination of cisplatinum in clean-
ing validation samples. The limit of quantiWcation of this
m e t h o d ,  w a s  5 0 0n gl ¡1, which is high compared to the lim-
its achievable with for example ICP-MS or voltammetry.
Schmaus et al. (2002) reported the validation of a voltam-
metric method with a limit of quantiWcation of 40 pg of
platinum per sample.
In the present study, we describe the development and
validation of an ICP-MS method for the evaluation of sur-
face contamination by platinum originating from cisplati-
num, oxaliplatinum, and carboplatinum. ICP-MS assures an
ultra high sensitivity and speciWcity and requires relatively
simple sample pre-treatment procedures. The validated
method has been applied to measure surface contamination
in seven Dutch hospital pharmacies.
Experimental
Chemicals
Cisplatinum and carboplatinum reference standards were
purchased from Calbiochem (San Diego, CA, USA). Oxali-
platinum was obtained from Sigma-Aldrich (St Louis, MO,
USA). Chloroplatinic acid, containing 1,000 mg l¡1 platinum
in 3.3% HCl, used for preparation of calibration solutions,
was obtained from Inorganic Ventures/IV Labs (Lakewood,
NJ, USA). Iridium chloride, containing 1,000 mg l¡1 irid-
ium in 3.3% HCl, used for internal standardisation, was
also purchased from Inorganic Ventures/IV Labs. Nitric
acid (HNO3) 70% and hydrochloric acid (HCl) 35% Ultrex
II ultrapure reagents were obtained from Mallinckrodt
Baker (Philipsburg, NJ, USA). Water used for the ICP-MS
analysis was sterile water for irrigation (Aqua B. Braun
Medical, Melsungen, Germany). Ethanol 80% was pur-
chased from Fresenius Kabi (Den Bosch, The Netherlands).
A multi-element solution containing 10 mg l¡1 of Ba, Be,
Ce, Co, In, Mg, Pb, Th, Tl (VAR-TS-MS) was purchased
from Inorganic Ventures/IV Labs. Hoek Loos (Schiedam,
The Netherlands) provided argon gas (4.6) with 99.996%
purity.Int Arch Occup Environ Health (2007) 80:689–699 691
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Instrumentation
Analyses were performed on an ICP-quadrupole-MS (Var-
ian 810-MS) equipped with a 90° reXecting ion mirror
(Varian, Mulgrave, Victoria, Australia). The sample intro-
duction system consisted of a Micromist glass low Xow
nebuliser (sample uptake 0.4 ml min¡1), a peltier-cooled
(4°C) double pass glass spray chamber and a quartz torch.
The spray chamber was cooled to reduce the vapour load-
ing on the plasma, increasing the available energy for atom-
isation and ionisation of the elements of interest. Sample
transport from the SPS-3 autosampler (Varian) to the neb-
uliser was performed using a peristaltic pump (Watson-
Marlow Alitea, Stockholm, Sweden). The instrument was
cooled by using a Kühlmobil 142 VD (Van der Heijden,
Dörentrup, Germany). Data were acquired and processed
using the ICP-MS Expert Software version 1.1 b49 (Var-
ian). Further data handling was performed using Excel
2000 (Microsoft, Redmond, WA, USA). All measurements
were carried out in a dedicated temperature-controlled, pos-
itively pressurised environment in order to maintain opti-
mum instrument performance and minimise exogenous
contamination. All solutions were prepared using pipettes
(Falcon, Becton Dickinson Labware, Franklin Lakes, NJ,
USA) and polypropylene tubes 10 ml (Plastiques-Gosselin,
Hazebrouck Cedex, France) and 30 ml (Sarstedt AG&Co,
Nümbrecht, Germany). Filters (Minisart) used for Wltration
of wipe samples were obtained from Sartorius (Hannover,
Germany). Prior to method development, tubes were
checked thoroughly for platinum, iridium, and hafnium
contamination and appeared to be suitable for platinum
analyses.
Determination of platinum by ICP-MS
To optimise the ICP-MS signal for the high masses and to
reduce the formation of oxides, a solution containing
1,000 ng l¡1 of Th, In, Ce, Ba and Pt was used. Typically
this 1,000 ng l¡1 solution gave readings of 115In,
7 £ 105 cs ¡1; 232Th, 1 £ 106 cs ¡1 and 194Pt, 2 £ 105 cs ¡1.
The production of CeO+ was less than 1.0% of the total Ce+
counts. The formation of doubly charged Ba++ was less
than 3%. Performance was checked daily.
The platinum isotope used for calculation of platinum
concentrations was 194Pt. Iridium was used as internal stan-
dard. Detection of platinum can be subject to the interfer-
ence of hafmium oxides (Lustig et al. 1997). Therefore,
hafmium signals were monitored for all samples. The
detection mode for all isotopes was based on peak jumping
with peak dwell times of 50 ms, 25 scans per replicate, and
three replicates per sample. Quantitation was based on the
mean concentration of three replicates analysed against a
calibration curve using weighted linear regression analysis.
Assay development
The most suitable wipe material, desorption solvent, and
wipe solvent were selected using one surface sampling and
desorption procedure. This will be described below. Recov-
ery data were assessed for the three most commonly used
platinum agents; cisplatinum, oxaliplatinum, and carboplat-
inum. The diVerent molecular structures and, as a result, the
variable physical characteristics, might possibly lead to a
variation in absorption and desorption characteristics.
Therefore, we decided to evaluate all three compounds
instead of choosing one reference compound.
Surface sampling and desorption procedure
Each wipe tissue was moistened with 500 l wipe solvent. In
general, sampling was performed by wiping a deWned surface
area of 10 cm £ 10 cm. However, for surfaces for which it
was not possible to take a 10 cm £ 10 cm sample, the com-
plete top of the device was sampled and the area was esti-
mated. All wipe samples were collected with a uniform
sampling procedure by wiping in three diVerent directions
(vertical, horizontal, and diagonal). Wipe samples were
stored in 50 ml disposable polypropylene Xasks (Falcon,
Becton Dickinson Labware, Franklin Lakes, NJ, USA) at
¡20°C until further processing. Prior to analysis, 10 ml of
desorption solvent was added to the sample and Xasks were
kept in an ultrasonic bath for 60 min. Then, samples were
Wltered to remove particles which could possibly obstruct the
ICP-MS nebuliser, or could interfere with the analysis. Two
millilitres of sample were, after addition of iridium as inter-
nal standard, introduced directly into the ICP-MS. Samples
of locations which were expected to be highly contaminated,
were diluted prior to analysis to prevent contamination of the
sample introduction system of the ICP-MS.
Wipe material
A variety of wipe tissues are available for collecting samples
of surface contaminants. These vary in type of material, sur-
face area, and content of platinum contaminants. Three types
of wipes were evaluated for this study; Kimtech Science pre-
cision wipes (Kimberley-Clark Professional, Irving, TX,
USA), Whatman glass Wbre  Wlters (Schleicher&Schuell
Microscience GmbH, Dassel, Germany), and Klinion non-
woven gauzes (Medeco, Oud-Beijerland, The Netherlands).
The tissues were checked for platinum contamination and for
their ability to release platinum from stainless steel surfaces.
Desorption solvent
One percent HNO3 (v/v), 5% HNO3 (v/v), and 1% HCl (v/v)
were evaluated as desorption solutions. Kimtech Science692 Int Arch Occup Environ Health (2007) 80:689–699
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precision wipes were spiked with cisplatinum, oxaliplati-
num, and carboplatinum and the platinum recovery was
determined after desorption with 10 ml of each solvent.
Wipe solvent
Initially, water, 1% HCl, and 80% ethanol were selected
as wiping solutions. To investigate the capability of these
solutions to eVectively wipe surfaces, 100 cm2 stainless
steel surfaces were spiked with cisplatinum, oxaliplati-
num, and carboplatinum. These surfaces were subsequently
wiped and samples were desorbed using a 1% HCl
solution.
Validation procedures
Linearity
For calibration, the chloroplatinic acid reference solution
containing 1,000 mg l¡1 platinum was diluted with 1% HCl
to obtain working solutions with concentrations ranging
from 50.0 to 5.00 £ 103 ng l¡1 platinum. Working solu-
tions were diluted with 1% HCl to obtain calibration stan-
dards, ranging from 0.500 to 100 ng l¡1 platinum. Before
analysis, 15 l of iridium internal standard solution was
added to 1.5 ml of each calibration standard (Wnal internal
standard concentration 100 ng l¡1). The seven non-zero cal-
ibration standards were processed and analysed in singular
in three separate analytical runs. The calibrations were
back-calculated from the responses. Deviations from the
nominal concentration were evaluated.
Recovery and precision
Quality control (QC) samples were prepared to obtain
information on the recovery and precision of the desorption
method and platinum analysis. These samples were analy-
sed in the validation runs and subsequently also during the
analysis of the wipe samples of each hospital pharmacy.
Therefore, stock solutions of the platinum agents in water,
each containing a concentration of drug equivalent to
400 mg l¡1 platinum, were prepared. These stock solutions
were further diluted to obtain spiking solutions with con-
centrations ranging from 10.0 to 2.00 £ 103 ng l¡1. Tissues
were spiked with these solutions serving as QC samples at
the following concentration levels; 5.00 £ 10¡3,
2.5 £ 10¡2, 0.100, and 1.00 ng platinum on the tissues, cor-
responding to 0.500, 2.50, 10.0, and 100 ng l¡1 platinum in
the  Wnal solution. These tissues were processed as
described earlier. Three replicates of each sample were
analysed in three analytical runs. Recovery was expressed
as a percentage of the nominal concentration. Within-run
and between-run precisions were calculated by analysis of
variances (ANOVA) for each test concentration using the
analytical run as the grouping variable.
Two of the most important surfaces, stainless steel and
linoleum, were used to obtain information on the recovery
and within-run and between-run precisions of the complete
sampling procedure, including both wiping and desorption.
Therefore, 1.00 ng of cisplatinum, oxaliplatinum, or carbo-
platinum was pipetted in triplicate on a 100 cm2 stainless
steel and linoleum surface. After drying overnight, surfaces
were wiped following the previously described procedure
and analysed using ICP-MS. Three replicates of each sam-
ple were analysed in three analytical runs for both surfaces.
Recovery was expressed as a percentage of the nominal
concentration. Within-run and between-run precision were
calculated by ANOVA for each test concentration using the
analytical run as the grouping variable.
Sensitivity
The lower limit of quantitation (LLOQ) was deWned as the
concentration at which the analyte response was at least
Wve times the response of a blank wipe sample. Besides, the
LLOQ, when spiked on blank tissues, had to be determined
with a precision less than 20% and the mean value should
not deviate more than 20% of the actual value.
Stability
Stability of cisplatinum, oxaliplatinum, and carboplatinum
spiked to tissues, at two concentration levels, was evaluated
at ambient temperatures for 1 week and under storage con-
ditions (¡20°C) for up to 3 weeks. From each storage con-
dition two wipe samples were analysed. Samples were
considered stable when 80–120% of the initial concentra-
tion was recovered.
Platinum determination in pharmacy facilities 
where no cytotoxic agents are processed
Platinum is an element that not only appears in the environ-
ment due to contamination with platinum containing cyto-
toxic drugs, but also due to pollution by car exhaust
catalysts. As a consequence, road dust also contains plati-
num (Barefoot 1997). Even though, in the pharmacy facili-
ties, precautions (use of slippers/clogs) are taken to reduce
the chance of contamination of the facility, road dust con-
tamination might occur. Because ICP-MS does not diVeren-
tiate between the sources of elemental platinum, this should
be taken into account when considering this technique for
evaluation of environmental contamination by cytotoxic
platinum agents. Therefore, two additional locations were
included in this study to set a threshold below which it was
not possible to address the source of the contamination. TheInt Arch Occup Environ Health (2007) 80:689–699 693
123
Wrst location was the laminar-airXow (LAF) hood in a clean
room in which no platinum contamination was expected.
The second location was a preparation unit with LAF hood
of a public pharmacy.
Monitoring of surface contamination 
in seven Dutch hospital pharmacies
The wipe samples were taken in seven hospital pharmacies
in The Netherlands. Characteristics of the facilities are
shown in Table 1. The facilities were selected to provide a
representation of the diversity in hospital pharmacies in The
Netherlands in terms of size and amount of platinum com-
pounds handled. The facilities of each hospital consisted of a
preparation room with at least one LAF hood and a room for
storage and checking of the prepared drugs and administra-
tion purposes. In each facility, samples were taken at loca-
tions that were prone to contamination. For good
comparison of the results 15 standard locations (Fig. 1) were
selected: (1) the middle of the bench-top of the LAF hood,
(2) front edge of LAF hood, (3) Xoor in front of LAF hood,
(4) handle of service hatch, (5) door handle, (6) waste bin
top, (7) bench-top on which materials are placed in storage/
checking room, (8) Xoor in front of (7), (9) mouse computer,
(10) handle telephone, (11) storage shelve of cisplatinum,
(12) storage shelve oxaliplatinum, (13) storage shelve carbo-
platinum, (14) transport box, (15) handle refrigerator. Loca-
tions 1, 2, and 3 were sampled in duplicate to get an
impression of the overall contamination of these locations.
A new pair of gloves was used for each wipe sample. For
each facility three blank samples were prepared by moisten-
ing tissue with 500 l water. All samples were stored and
processed as described earlier. The storage time from sam-
pling until work-up procedure was less than 2 weeks.
Wipe sampling was announced in each facility in advance
and was performed after the daily cleaning procedure of the
Table 1 Amount of platinum agents processed and years that the facilities are in service
Site
123 456 7
Cisplatinum use in 2005 (in g) 52.3 6.80 64.0 147 16.8 29.9 104
Oxaliplatinum use in 2005 (in g) 47.5 8.65 44.1 109 23.4 98.8 62.0
Carboplatinum use in 2005 (in g) 256 48.2 124 635 56.5 223 217
Total amount of platinum 
processed in 2005 (in g) 
192 34.0 129 483 52.1 185 212
Number of years in service 5 10 18 2.5 1.5 10 15
Wipe sampling frequency Once 
per year
2005 Wrst 
time
Sporadic: 
last in 2004
Once 
per year
Once 
per year
Once 
per year 
Twice 
per year
Fig. 1 Sample locations in 
pharmacy facilities694 Int Arch Occup Environ Health (2007) 80:689–699
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LAF hoods, but before the daily cleaning procedure of the
rest of the facility. Wipe sampling in all the facilities was
performed by the same person.
Results
Assay development
Wipe material
As a result of high platinum backgrounds (10–20 pg plati-
num per Wlter depending on the batch analysed), Whatman
glass Wbre Wlters were found to be not suitable for platinum
wipe sampling. Kimtech Science precision wipes and Kli-
nion non-woven gauzes did not show platinum contamina-
tion. However, Kimtech Science precision wipes showed
better recoveries of platinum compared to Klinion non-
woven gauzes and consequently Kimtech Science precision
wipes appeared to be the best choice.
Desorption solvent
The most eVective desorption of platinum from the wipe
materials was achieved by 1% HCl (94–99%). As a result
1% HCl was selected as the desorption solution of choice.
Wipe solvent
Recoveries were inadequate for 80% ethanol (<40% for all
three compounds) and acceptable for water (50–77%) and
1% HCl (63–78%). Because 1% HCl appeared to be corro-
sive for some types of stainless steel, water was selected as
wipe solution.
Validation procedures
Linearity
The calibration curve was best described by linear regres-
sion, using 1/(sd of triplicate sample reading) as weight-fac-
tor, to avoid bias in favour of samples with high standard
deviations. Deviations from the nominal concentration were
between ¡10.0 and 10.2 for all concentration levels. Rela-
tive standard deviations for the calibration samples were up
to 7.84%. Correlation coeYcients were higher than 0.99999.
Recovery and precision
Within-run and between-run precision data for spiked tissues,
which served as QCs are summarised in Table 2. Precision
data showed that, for all QC concentration levels, the repro-
ducibility of the desorption procedure and platinum analysis
was excellent. Recoveries for cisplatinum, oxaliplatinum, and
carboplatinum were between 86.7 and 103% for all concen-
tration levels. These results indicated suYcient recovery.
For recovery and within-run and between-run precision
data from the spiked stainless steel and linoleum surfaces
see, respectively, Tables 3 and 4. Precision data showed
that the reproducibility of the method, including the wiping
procedure was good. Recoveries from the spiked stainless
steel surface were 50.4% for cisplatinum, 73.8% for oxali-
platinum, and 77.2% for carboplatinum (Table 3). Recover-
ies for the linoleum surface were, respectively, 76.8, 77.9,
and 81.4% (Table 4).
Sensitivity
The LLOQ of the assay was set at a platinum concentration
of 0.5 ng l¡1 in 1% HCl, corresponding to 5 pg per wipe
sample or 0.05 pg cm¡2 taking into account a surface of
10 cm £ 10 cm. Signal to noise ratios at the LLOQ level
exceeded 5 during all the experiments, which was in accor-
dance with the requirement. The acceptance criteria, that the
LLOQ was determined with a precision less than 20% and
that the mean value should deviate no more than 20% from
the actual value, were met for all three compounds (Table 2).
Stability
Stability has now been established up to 3 weeks, but
further testing is still ongoing. Sample storage at room
Table 2 Within and between-run precision data for quality control samples
a No statistically signiWcant additional value was observed as a result of performing the assay in diVerent runs (mean square within runs is greater
than mean square between runs)
Amount of platinum 
spiked to tissue (in ng)
Final platinum 
concentration (in ng l¡1)
Cisplatinum Oxaliplatinum Carboplatinum
Within-run Between-run Within-run Between-run Within-run Between-run
5.00 £ 10¡3 0.500 7.75 a 8.53 a 8.01 8.75
2.50 £ 10¡2 2.50 4.10 4.05 1.66 1.15 2.39 a
0.100 10.0 1.35 7.44 1.75 1.27 2.86 2.50
1.00 100 1.07 7.79 1.63 a 0.84 1.96Int Arch Occup Environ Health (2007) 80:689–699 695
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temperature for 1 week was not possible. Tissues which
were spiked with cisplatinum showed a decrease in plati-
num levels of 30% after 1 week. Oxaliplatinum and carbo-
platinum spiked tissues did not reduce under these
conditions. Sample storage at ¡20°C was possible for at
least 3 weeks. Platinum concentrations of cisplatinum
spiked tissues were decreasing more obvious with time than
oxaliplatinum and carboplatinum spiked tissues. However,
no decrease of more than 20% of the initial concentration
was observed after 3 weeks at ¡20°C.
Platinum determination in pharmacy facilities where no 
cytotoxic agents are processed
No platinum was detected in wipe samples from the LAF
hood of the public pharmacy. Platinum levels of the LAF
hood in the clean room and the Xoor in the public pharmacy
ranged between 0.430 and 0.922 ng l¡1 (or 0.0430–0.0922
pg cm¡2). Therefore, it was recommended to set a threshold
of 1.00 ng l¡1 platinum (0.100 pg cm¡2 when wiping a sur-
face of 100 cm2), below which it was not possible to
address the source of the contamination. All surfaces in the
preparation units with platinum levels above this threshold
were considered as being contaminated by platinum
containing drugs.
Monitoring surface contamination in seven Dutch hospital 
pharmacies
In February 2006, wipe samples were collected from seven
Dutch hospital pharmacies with centralised units dedicated
to the preparation of intravenous mixtures of cytotoxic
drugs. The amount of platinum which was processed in
these facilities ranged from 34.0 to 483 g per year
(Table 1). Surface contamination of all sample locations is
depicted in Table 5 in pg cm¡2. It is important to consider
that recoveries of the samples, as assessed in the validation
study, deviate from 100% dependent on the type of surface
sampled and on the type of compounds present on the sur-
face. Therefore, results depicted in Table 5 represent
¸50.4% of the actual contamination present on the surface.
Platinum was detected in 94% of the wipe samples and
88% of the samples contained levels above the threshold
set. Six of the 126 samples showed raised hafmium signals
which, considering a maximum oxide formation of 1%,
might have accounted for up to 20% of the platinum signals
of these samples. None of blank samples prepared for each
facility by moistening tissues with wipe solvent, contained
levels of platinum exceeding 20% of the LLOQ standard.
The variation in the level of contamination between phar-
macies was high. Pharmacies of site 1 and 5 showed overall
low platinum contaminations. For these sites, respectively
33 and 39% did not contain platinum levels above the
threshold set. Platinum levels detected at pharmacy 3 were
relatively low as well, although the wipes taken from the
Xoor were high at this site. These high values were, most
probably, the result of a calamity in 2005 with a cisplati-
num infusion mixture, which was spilled on the Xoor. Most
locations wiped at the hospital pharmacies of site 2, 4, 6,
and 7 showed high contaminations. Only one sample from
these sites did not contain any detectable platinum. The
high contamination of site 2 seemed to run counter to the
quantities of drugs handled, because in this pharmacy rela-
tively low amounts of platinum were processed. This site,
however, was occasionally used, for preparation of larger
amounts of cytotoxic drugs to serve another hospital.
Therefore, the amount of drugs processed in 2005, was not
fully representative for the amount of drugs processed in
the 10 years that this site was in use. Site 4 showed the
highest contamination, which paralleled the relative amount
of drug handled in this unit.
As expected, platinum was found in most wipe samples
taken from the middle of the LAF hood bench. Notable was
that, in general, wipe samples of the front edge of the LAF
hood were more contaminated than samples taken from the
bench-top of the LAF hood. Furthermore, Xoor samples
usually contained the highest platinum levels. Other loca-
tions showing substantial contamination were storage shelves,
door handles, and handles of service hatches. Duplicate
Table 3 Recovery of 1.00 ng platinum from a stainless steel surface
a No statistically signiWcant additional value was observed as a result
of performing the assay in diVerent runs (mean square within runs is
greater than mean square between runs)
Cisplatinum Oxaliplatinum Carboplatinum
Mean recovery (%) 50.4 73.8 77.2
Within-run 
precision (in %)
2.21 4.63 2.53
Between-run 
precision (in %)
3.36 aa
Number of days 3 3 3
Number of samples 
per day
33 3
Table 4 Recovery of 1.00 ng platinum from a linoneum surface
Cisplatinum Oxaliplatinum Carboplatinum
Mean recovery (%) 76.8 77.9 81.4
Within-run 
precision (in %)
3.62 2.12 3.35
Between-run 
precision (in %)
12.2 5.41 6.82
Number of days 3 3 3
Number of samples 
per day
33 3696 Int Arch Occup Environ Health (2007) 80:689–699
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samples of locations 1, 2, and 3 showed similar results,
indicating a homogeneous distribution over de surface area.
The number of years that the seven units were in use, did
not parallel contamination levels and the amount of drug
handled in 2005, overall, did not predict the level of con-
tamination either.
Discussion
The presence of cytotoxic drug contamination in hospital
pharmacies is recognized as a potential health risk. There-
fore, it is important to monitor this contamination. Because
platinum coordination complexes belong to the most exten-
sively used anticancer agents, it is relevant to focus on the
occupational exposure of these drugs. The rationale for
evaluation of platinum contamination is also illustrated by
several studies showing increased levels of platinum in
blood (Nygren and Lundgren 1997) and urine (Ensslin et al.
1994a,  1997; Nygren and Lundgren 1997; Pethran et al.
2003; Schreiber et al. 2003; Turci et al. 2002) of hospital
personnel working with these agents.
To be able to accurately assess the platinum contami-
nation originating from cisplatinum, oxaliplatinum, and
carboplatinum at diVerent locations, we developed and
validated a wipe sampling method. ICP-MS was used for
quantiWcation of platinum, because this technique assures
a high sensitivity and relative simple sample pre-treat-
ment. The sensitivity of the method was excellent. The
LLOQ was set at a platinum concentration of 0.5 ng l¡1,
corresponding to 5 pg per sample or 0.05 pg cm¡2 when
wiping a surface of 100 cm2. To our best knowledge, the
method described here is 2–300 times more sensitive than
other methods described for determination of platinum in
wipe samples (Connor et al. 2005; Mason et al. 2003,
2005; Raghavan et al. 2000; Schmaus et al. 2002; Ziegler
et al. 2002).
Sample pre-treatment only involved surface sampling,
desorption, and Wltration. After Wltration, samples could be
analysed immediately. During method development it was
shown that, in addition to tissue material and desorption
solvent, also the wipe solvent aVected the recovery to a
considerable extent. This was in contrast with results
described by Turci et al. (2003), who mentioned that the
type of wipe solvent would not inXuence the recovery,
since contaminants would be wept away from the surfaces
independent of the composition or the pH of the solution
itself. Best recoveries were achieved by wiping with
Table 5 Platinum contamination in seven Dutch hospital pharmacies
a Recovered platinum concentrations were below the threshold
b Device was not present of available for wipe sampling
c Hafnium oxide might have accounted for up to 20% of the platinum content
S.no. Sampled surface Platinum contamination (in pg cm¡2)
Site
12 34 5 67
1 Middle of bench LAF hood 0.22 180 0.54 32.7 0.360 7.22 2.94
Duplicate of 1 0.189 124 0.645 18.7 0.328 8.22 2.28
2 Front edge of LAF hood –a 356 3.32 99.5 0.133 28.2 5.12
Duplicate of 2 –a 268 8.34 180 –a 37.0 5.19
3 Floor in front of LAF hood 3.14 173 824 1,107 0.228 2.48 21.7
Duplicate of 3 3.20 232 728 2,211 0.186 1.91 12.5
4 Handle of service hatch –a 22.7 –a 2,055 –a 1.96 11.8
5 Door handle –a 3.17 –a 16.8 –a 21.4 16.1
6 Waste bin top –a 1.02 0.392 10.1 –a 7.38 0.098c
7 Bench-top on which materials are placed 0.829 0.949 0.298 90.6 0.202 0.375 63.4
8 Floor in front of bench 0.105c 19.7 58.9 38.1 –a 0.311c 11.9
9 Mouse computer 0.252 0.816 1.34 10.2 –b 0.758 5.41
10 Handle telephone –a 3.22 0.59 12.1 –a 3.06 5.12
11 Storage shelve cisplatinum 0.176c 1.14 0.157c 4.76 0.536 4.04 336
12 Storage shelve oxaliplatinum 0.368 0.916 0.141c 4.10 82.7 1.15 2.21
13 Storage shelve carboplatinum 3.25 1.53 0.147 3.13 0.186 0.989 5,760
14 Transport box 74.5 –a 0.285 4.44 –a 0.828 –b
15 Handle refrigerator 0.452 26.3 1.46 36.0 0.948 1.42 5.71Int Arch Occup Environ Health (2007) 80:689–699 697
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Kimtech Science precision wipes moistened with 500 l
water and subsequent desorption with 1% HCl.
Validation of the method was performed for the three, in
oncology most prominently used platinum agents, cisplati-
num, oxaliplatinum, and carboplatinum. We decided not to
choose one reference compound, because the diVerent
molecular structures of the platinum agents and, as a result,
the variable physical characteristics, might possibly lead to
a variation in absorption and desorption characteristics.
Excellent reproducibility (imprecision up to 8.75%) and
recoveries (86.7–103%) were demonstrated with spiked tis-
sues, for all concentration levels and compounds. Up to
13.3% of the initial amount of platinum added to the tissues
was not recovered after desorption and analysis. This could
be due to variation in analysis, as well as loss due to
adsorption to the tissues. Recoveries from the spiked stain-
less steel surface were 50.4% for cisplatinum, 73.8% for
oxaliplatinum, and 77.2% for carboplatinum. Recoveries,
for the three compounds, from the linoleum surface were,
respectively, 76.8, 77.9, and 81.4%. These results showed
that for stainless steel, depending on the compound analy-
sed, up to 49.6% of the initial amount of platinum spiked to
the surface was lost. This was, for the greater part, caused
by the inability of the wipe procedure to remove all the
added platinum and, for a minor part, by the variation in
analysis and loss due to adsorption to the tissues. The lower
recovery that was observed for cisplatinum, is, most proba-
bly, a consequence of its superior reactivity compared to
oxaliplatinum and carboplatinum. This might lead to a
stronger binding aYnity of cisplatinum to materials and
surfaces. For linoleum up to 23.2% of the initial amount of
platinum spiked to the surface was not recovered. For this
surface, recoveries were similar for all compounds.
To evaluate the stability of spiked samples, recoveries
were assessed after storage at room temperature and
¡20°C. Storage of spiked tissues at ¡20°C for at least 3
weeks was possible. However, storage of tissues spiked
with cisplatinum for 1 week at room temperature led to
considerable decrease in platinum levels. Even though plat-
inum concentrations from oxaliplatinum and carboplatinum
spiked tissues did not reduce under these conditions, stor-
age at room temperature was not recommended, also
because the source of elemental platinum is not known in
wipe samples performed in pharmacies. DiVerences in
recovery of the cisplatinum and the oxaliplatinum and car-
boplatinum spiked samples, again, could be explained by
the higher reactivity of cisplatinum.
For a correct interpretation of surface sampling results, it
is relevant to take into account that platinum is an element
that not only appears in the environment due to contamina-
tion with platinum containing cytotoxic drugs, but also due
to pollution by car exhaust catalysts. By wipe sampling two
locations where no cytotoxic drugs were handled, we,
therefore, determined that below a threshold of 1.00 ng l¡1
platinum (0.100 pg cm¡2 when wiping a surface of
100 cm2), it was not possible to address the source of con-
tamination. All surfaces in the preparation units with plati-
num levels above the threshold were considered as being
contaminated by platinum containing drugs.
Taking this threshold into consideration, platinum con-
tamination was reported in 88% of the samples taken in the
seven Dutch hospital pharmacies. It is important to con-
sider that recoveries of the samples, as assessed in the vali-
dation study, deviate from 100% dependent on the type of
surface sampled and on the type of compounds present on
the surface. Therefore, results depicted in Table 5 represent
¸50.4 of the actual contamination present on the surface.
The results of this study indicate that there is substantial
variation in surface contamination of the pharmacies tested
and that the amount of platinum processed in the pharma-
cies did not always parallel the level of contamination. The
number of preparations with platinum drugs was, however,
not assessed and might also be related to surface contami-
nation. This suggests that variation in the application of or
compliance to cleaning and working procedures and the
incidence of calamities, rather than the amount of platinum
processed, caused variation in surface contamination.
In general, results reveal that the LAF hoods, the Xoor in
front of the LAF hoods, door handles, and handles of ser-
vice hatches were often contaminated. This demonstrates
that contamination is often spread throughout the phar-
macy. Notable was that wipe samples of the front edge of
the LAF hood were more contaminated than samples from
the bench-top of the LAF hood. This is thought to be due to
incorrect application of working procedures or insuYcient
cleaning.
By taking duplicate wipe samples of the LAF hood, the
front edge of the LAF hood, and the Xoor, we demonstrated
that these locations were overall contaminated and that con-
tamination did not appear to be spotty as was mentioned by
Zeedijk et al. (2005).
We also investigated storage shelves and, in most phar-
macies, considerable platinum contamination was found.
These elevated levels could be a consequence of elevated
levels of platinum on packaging material (Connor et al.
2005; Mason et al. 2003; Nygren et al. 2002). Contamina-
tion of packaging can lead to a spread of cytotoxic drugs to
locations where the drugs are stored or processed. There-
fore, it was not surprising that the storage shelves of plati-
num agents were contaminated. Furthermore, it was noticed
that in at least one of the hospital pharmacies (at site 4),
secondary packaging and caps of the vials were discarded
onto the Xoor during preparation, most probably to prevent
the packaging from interfering with preparation activities.
This pharmacy indeed showed considerable contamination
of the Xoor.698 Int Arch Occup Environ Health (2007) 80:689–699
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In our study, surfaces showed platinum contamination of
up to 5,760 pg cm¡2. The results are in the same range as
Wndings of some other studies describing surface contami-
nation of platinum in hospital pharmacies (Leboucher et al.
2002; Schmaus et al. 2002). In the study of Leboucher et al.
(2002), however, no platinum was found outside the LAF
hood, which could be due to the high detection limit of the
atomic absorption spectrometry method used (10 gl ¡1).
Schmaus et al. (2002) performed a study in 14 hospital
pharmacies and all samples tested positive for platinum,
even though the LLOQ of their method was eight times
higher than of the method described here. Yet, although in
our study not all samples tested positive for platinum, the
highest contamination found (5,760 pg cm¡2) was compa-
rable to the highest contamination found by Schmaus et al.
(2,700 pg cm¡2). Mason et al. (2005) showed lower con-
tamination levels than found in our study, despite that the
amount of drug handled in these pharmacies was higher
than in the pharmacies in our study.
When comparing the amounts of platinum detected on
diVerent locations in this study (up to 0.576 g per wipe
sample) with the platinum content of one vial (between
6.50 and 237 mg platinum), contamination seems to be rel-
atively low. Furthermore, the extremely sensitive technique
used in this study, leads to a high percentage of positive
samples. Interpretation of these results is rather compli-
cated. It is important to consider that the total area of the
contamination is large and that pharmacy personnel are at
risk to be exposed to the contamination daily. Hence, for
safety precautions, it is recommended to attempt to achieve
the lowest possible contamination. Environmental monitor-
ing therefore, may be used to monitor and control contami-
nation and thereby evaluate working and cleaning
procedures, rather than to interpret potential health risks.
In general, when a minimal contamination level is
desired, the results of this study demonstrate that cleaning
and working procedures do not suYciently prevent contam-
ination in most hospitals. This could be due to an inade-
quate compliance of personnel to these procedures.
Moreover, contamination can spread out unconsciously by
hands or feet of the personnel. It is also likely that cleaning
procedures as applied in the diVerent pharmacies are not
fully optimised and validated, leading to contamination due
to sub-optimal cleaning. With respect to the physical prop-
erties of the diVerent cytotoxic drugs, it is recommended to
consider cleaning techniques appropriate for speciWc
agents. As was shown in this study for platinum, for
instance, 80% ethanol did not eVectively remove platinum
from a stainless steel surface. Although water gave better
recoveries for platinum, it was not capable of removing all
of the added platinum from the stainless steel surface. This
illustrates the importance to evaluate several cleaning pro-
cedures for the diVerent cytotoxic agents handled and to
optimise a procedure which does remove all drugs with
acceptable recoveries.
In conclusion we developed and validated an ultra sensi-
tive and reliable ICP-MS method for the determination of
platinum in surface samples. This method was successfully
applied in the evaluation of platinum contamination in the
preparation units of seven Dutch hospital pharmacies. It
was demonstrated that pharmacy personnel is at risk to be
exposed to platinum, despite the use of cleaning and safety
procedures. As long as the consequences of long-term
exposure are not known, the aim should be to achieve a
contamination levels as low as possible. This study, there-
fore, highlights the need to further evaluate cleaning and
safety procedures. Wipe sampling can be applied to quan-
tify improvements made through changes in procedures.
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